Premedication and Chemotherapy Agents Do Not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-14-2579
Full Text
Open PDFAbstract
Available in full text
Date
November 18, 2015
Authors
Publisher
American Association for Cancer Research (AACR)